{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:19:44Z","timestamp":1785529184999,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.clinthera.2009.02.015","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T07:45:18Z","timestamp":1237448718000},"page":"299-310","source":"Crossref","is-referenced-by-count":14,"title":["Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: A single-center, open-label, prospective, observational study"],"prefix":"10.1016","volume":"31","author":[{"given":"Eli N.","family":"Deal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Micek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Reichley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.02.015_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1592\/phco.2006.26.1.129","article-title":"Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the Society of Infectious Diseases Pharmacists","volume":"26","author":"Ambrose","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2009.02.015_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore [published correction appears in Clin Infect Dis. 2007;44:624]","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2009.02.015_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0732-8893(00)00185-1","article-title":"The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae","volume":"38","author":"Ambrose","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2009.02.015_bib4","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1128\/AAC.48.7.2464-2470.2004","article-title":"Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002","volume":"48","author":"Kuti","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.02.015_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.02.018","article-title":"Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections","volume":"28","author":"Kuti","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2009.02.015_bib6","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1592\/phco.26.9.1320","article-title":"Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists","volume":"26","author":"Lodise","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2009.02.015_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/dkh511","article-title":"The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe [published correction appears in J Antimicrob Chemother. 2005;56:990]","volume":"55","author":"Masterton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.02.015_bib8","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clinthera.2005.06.013","article-title":"A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit","volume":"27","author":"Mouton","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2009.02.015_bib9","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1097\/01.CCM.0000181528.88571.9B","article-title":"Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: A report from the OPTAMA Program","volume":"33","author":"Sun","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2009.02.015_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2146\/ajhp050210","article-title":"An integrated pharmacoeconomic approach to antimicrobial formulary decision-making","volume":"63","author":"Tam","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2009.02.015_bib11","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.47.5.1643-1646.2003","article-title":"Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: Report from the ARREST program","volume":"47","author":"Ambrose","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2009.02.015_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1469-0691.2005.01265.x","article-title":"Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations","volume":"11","author":"Andes","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2009.02.015_bib13","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.clinthera.2005.11.007","article-title":"Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: A report from the OPTAMA program","volume":"27","author":"Ellis","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2009.02.015_bib14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ijantimicag.2006.05.031","article-title":"Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil","volume":"28","author":"Kiffer","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2009.02.015_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1128\/AAC.49.1.461-463.2005","article-title":"Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation","volume":"49","author":"Lomaestro","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.02.015_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijantimicag.2006.07.014","article-title":"Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals","volume":"28","author":"Ludwig","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2009.02.015_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2004.08.012","article-title":"Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion","volume":"25","author":"Buck","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2009.02.015_bib18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1469-0691.2005.01106.x","article-title":"Continuous infusion beta-lactams for intensive care unit pulmonary infections","volume":"11","author":"Frei","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2009.02.015_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.iccn.2004.07.011","article-title":"The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion","volume":"21","author":"Kotapati","year":"2005","journal-title":"Intensive Crit Care Nurs"},{"key":"10.1016\/j.clinthera.2009.02.015_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijantimicag.2005.06.004","article-title":"Pharmacodynamics of intermittent and continuous infusion piperacillin\/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms","volume":"26","author":"Reese","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2009.02.015_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2009.02.015_bib22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/jac\/49.3.445","article-title":"Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime","volume":"49","author":"Ambrose","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.02.015_bib23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5414\/CPP43360","article-title":"Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen","volume":"43","author":"Georges","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2009.02.015_bib24","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1211\/002235702171","article-title":"Continuous infusion versus intermittent administration of cefepime in patients with Gramnegative bacilli bacteraemia","volume":"54","author":"Jaruratanasirikul","year":"2002","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.clinthera.2009.02.015_bib25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkl349","article-title":"Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units","volume":"58","author":"Roos","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.02.015_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1592\/phco.23.3.291.32110","article-title":"Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa","volume":"23","author":"Tam","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2009.02.015_bib27","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/AAC.47.6.1853-1861.2003","article-title":"Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function","volume":"47","author":"Tam","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.02.015_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.02.015_bib29","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1128\/AAC.01487-06","article-title":"Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms","volume":"51","author":"Bhat","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.02.015_bib30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: A systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2009.02.015_bib31","series-title":"Maxipime (cefepime) [package insert]","year":"2007"},{"key":"10.1016\/j.clinthera.2009.02.015_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.clinthera.2009.02.015_bib33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: A severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2009.02.015_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clinthera.2009.02.015_bib35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1164\/ajrccm.162.2.9909095","article-title":"Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription","volume":"162","author":"Singh","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2009.02.015_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/sur.2006.7.331","article-title":"Can the clinical pulmonary infection score impact ICU antibiotic days?","volume":"7","author":"Swoboda","year":"2006","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.clinthera.2009.02.015_bib37","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1128\/JCM.43.12.5945-5949.2005","article-title":"Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp, Citrobacter spp, and Serratia spp","volume":"43","author":"Dunne","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2009.02.015_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1592\/phco.27.2.191","article-title":"Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii","volume":"27","author":"Deal","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2009.02.015_bib39","volume":"vol. 19","year":"1999"},{"key":"10.1016\/j.clinthera.2009.02.015_bib40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7326\/0003-4819-118-3-199302010-00009","article-title":"The risk of determining risk with multivariable models","volume":"118","author":"Concato","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2009.02.015_bib41","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.02.015_bib42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.118.1.146","article-title":"The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting","volume":"118","author":"Ibrahim","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2009.02.015_bib43","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1378\/chest.115.2.462","article-title":"Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients","volume":"115","author":"Kollef","year":"1999","journal-title":"Chest"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T20:52:20Z","timestamp":1545339140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0149291809000587"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.02.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}